Drug Profile

SUN 13837

Alternative Names: SUN-13837

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Asubio Pharmaceuticals
Developer Daiichi Sankyo Company
Class Small molecules
Mechanism of Action Fibroblast growth factor receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Spinal cord injuries; Stroke

Most Recent Events

01 Apr 2015 Asubio Pharmaceuticals completes enrolment in a phase II trial in Spinal cord injuries in USA, Canada, Czech Republic, France, Poland and United Kingdom (NCT01502631)
01 Mar 2015 Asubio Pharmaceuticals completes a phase II trial in Spinal cord injuries in USA, Canada, Czech Republic, France, Poland and United Kingdom (NCT01502631)
29 Jan 2015 Discontinued- Phase-II for Stroke in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com